Basilea is at the forefront of developing novel antibiotics to combat multidrug resistant bacterial infections

Basilea is at the forefront of developing novel antibiotics to combat multidrug resistant bacterial infections. The company’s key product, Zevtera® (ceftobiprole), is a broad spectrum cephalosporin antibiotic designed to treat severe bacterial infections, including hospital−acquired pneumonia and community acquired pneumonia.Basilea is also focused on addressing fungal infections with innovative therapies. Cresemba® (isavuconazole) is an antifungal medication used to treat invasive aspergillosis and mucormycosis, two life−threatening fungal infections prevalent in immunocompromised patients. Basilea Pharmaceutica places a strong emphasis on research and development to drive innovation and expand its therapeutic offerings:The company conducts extensive clinical trials to evaluate the safety, efficacy, and potential of its drug candidates. These trials are crucial for advancing therapies from early−stage development to regulatory approval and commercialization.Basilea collaborates with academic institutions, research organizations, and industry partners to enhance its R&D capabilities and accelerate the development of new treatments.